VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook

VRTX Raises Outlook as Investment Builds

Chief operating officer and CFO Charles Wagner said that second-quarter 2026 revenues rose 12% to $3.33 billion, topping the Zacks Consensus Estimate of $3.23 billion. Non-GAAP earnings of $4.73 per share missed the consensus estimate of $4.79 by 6 cents.

Wagner raised its full-year revenue guidance to $13.1-$13.2 billion from $12.95-$13.1 billion. The outlook still assumes at least $500 million from CASGEVY and JOURNAVX, and a 150-basis-point foreign-exchange benefit.

He kept non-GAAP operating expense guidance at $5.65-$5.75 billion but expects spending near the high end. The gross margin is expected just below 86%, reflecting product mix and manufacturing investments.

Vertex Reinforces CF Leadership

CEO and president Reshma Kewalramani emphasized ALYFTREK as the new standard of care in cystic fibrosis. Management said that global CF revenues grew 11%, supported by ALYFTREK uptake, TRIKAFTA demand and higher U.S. net pricing.

Chief commercial officer Duncan McKechnie said that ALYFTREK exceeded $1 billion in first-half revenues. Most sales came from patients switching from TRIKAFTA, with new, returning and rare-mutation patients also contributing.

Kewalramani set a demanding bar for next-generation CF programs. Vertex will advance assets only if they can move more patients below the 30-millimoles-per-liter sweat chloride threshold while retaining once-daily dosing and favorable drug properties.

VRTX Sees New Products Gaining Scale

Chief commercial officer Duncan McKechnie said that CASGEVY revenues were $76 million, surging about 75% sequentially and more than 150% year over year. More infusions occurred in the first half than in all of 2025.

JOURNAVX generated $50 million, with prescriptions rising about 45% sequentially to roughly 535,000. McKechnie said that prescription growth is ahead of the 2026 forecast, though inventory and patient-support usage continue to affect recognized revenues.

McKechnie expects gross-to-net levels to normalize in the first half of 2027. He tied the timing to payer restrictions and heavier patient-support use as physician adoption outpaces access education.

Vertex Positions Povetacicept for Launch

Kewalramani highlighted the Nov. 30 PDUFA date for povetacicept in IgA nephropathy and said that launch preparation is in its final stages. Vertex has completed hiring a renal field force, with about 90% bringing nephrology experience.

McKechnie said that the commercial case rests on efficacy, tolerability and once-monthly at-home administration. Vertex expects its field organization, payer work and patient-support programs to support adoption upon approval.

The renal pipeline extends beyond IgAN. Kewalramani said that inaxaplin’s AMPLITUDE interim analysis remains on track for early 2027, while AMPLIFIED results and VX-670 data in myotonic dystrophy type 1 are due in the second half of 2026.

VRTX Q&A Clarifies Key Benchmarks

A JPMorgan analyst asked whether new IgAN drugs could separate on kidney-function outcomes. Kewalramani said that deeper reductions in proteinuria, hematuria and disease-driving antibodies should matter through their effect on progression to dialysis, transplant or death.

A Citi analyst pressed on Vertex’s next CF generation. Kewalramani reiterated that sweat chloride distribution, safety, once-daily dosing and drug-drug interaction profiles will determine whether a candidate advances.

A Wells Fargo analyst asked about JOURNAVX treatment duration. McKechnie said that prescriptions average five days in hospitals and 12-14 days in retail, producing an overall average of 10-11 days that has remained stable.

Vertex Keeps Execution-First Posture

Management’s tone remained confident but spending-aware. The company is prioritizing launch execution in pain and renal while maintaining CF growth and advancing clinical readouts.

The pending Crinetics acquisition would add rare endocrine diseases as a fifth pillar. Guidance excludes the transaction, which Vertex expects to close in the third quarter before updating its 2026 outlook.

Zacks Signals Mixed Setup

VRTX currently carries a Zacks Rank #3 (Hold), a neutral near-term signal. Its Value Score and Growth Score are C, while Momentum Score and VGM Score are D, indicating middle-range value and growth characteristics but weaker momentum and combined style positioning. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks Style Scores complement the Rank, with A or B scores preferred over lower grades. The current mix lacks strong style confirmation, and the Zacks Rank can change as analysts revise estimates after the reported results.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research